| Past, present and future of therapeutic strategies against amyloid-β peptides in Alzheimer’s disease: A systematic review D Jeremic, L Jiménez-Díaz, JD Navarro-López Ageing research reviews 72, 101496, 2021 | 255 | 2021 |
| Therapeutic potential of targeting G protein-gated inwardly rectifying potassium (GIRK) channels in the central nervous system D Jeremic, I Sanchez-Rodriguez, L Jimenez-Diaz, JD Navarro-Lopez Pharmacology & therapeutics 223, 107808, 2021 | 76 | 2021 |
| Efficacy and safety of anti-amyloid-β monoclonal antibodies in current Alzheimer's disease phase III clinical trials: A systematic review and interactive web app-based meta … D Jeremic, JD Navarro-López, L Jiménez-Díaz Ageing Research Reviews, 102012, 2023 | 42 | 2023 |
| Impairments of synaptic plasticity induction threshold and network oscillatory activity in the hippocampus underlie memory deficits in a non-transgenic mouse model of amyloidosis J Mayordomo-Cava, G Iborra-Lázaro, S Djebari, S Temprano-Carazo, ... Biology 9 (7), 175, 2020 | 23 | 2020 |
| Targeting epigenetics: A novel promise for Alzheimer’s disease treatment D Jeremic, L Jiménez-Díaz, JD Navarro-López Ageing Research Reviews, 102003, 2023 | 17 | 2023 |
| Recognition memory induces natural LTP-like hippocampal synaptic excitation and inhibition I Sánchez-Rodríguez, S Temprano-Carazo, D Jeremic, ... International Journal of Molecular Sciences 23 (18), 10806, 2022 | 16 | 2022 |
| Systematic characterization of a non-transgenic Aβ1–42 amyloidosis model: synaptic plasticity and memory deficits in female and male mice R Jiménez-Herrera, A Contreras, S Djebari, J Mulero-Franco, ... Biology of sex Differences 14 (1), 59, 2023 | 8 | 2023 |
| A systematic review of therapeutic strategies against amyloid‐β peptides in Alzheimer’s disease: Past, present, and future D Jeremic, L Jimenez‐Diaz, JD Navarro‐López Alzheimer's & Dementia 19, e060438, 2023 | 1 | 2023 |
| 阿尔茨海默病中的抗淀粉样蛋白抗体: 临床试验教会了我们什么? D Jeremic, L Jiménez-Díaz, JD Navarro-López 中国神经再生研究 (英文版) 20 (4), 1092, 2025 | | 2025 |
| Anti-amyloid antibodies in Alzheimer’s disease: what did clinical trials teach us? D Jeremic, L Jiménez-Díaz, JD Navarro-López Neural Regeneration Research 20 (4), 1092-1093, 2025 | | 2025 |
| Donanemab outperformed Aducanumab and Lecanemab on cognitive, but not on biomarker and safety outcomes: systematic review, frequentist and Bayesian network meta-analyses D Jeremic, JD Navarro-Lopez, L Jimenez-Diaz medRxiv, 2024.03. 31.24305134, 2024 | | 2024 |
| SYSTEMATIC CHARACTERIZATION OF A NON-TRANSGENIC AΒ1–42 AMYLOIDOSIS MODEL: SYNAPTIC PLASTICITY AND MEMORY DEFICITS IN FEMALE AND MALE MICE R Jiménez-Hererra, A Contreras, G Iborra-Lázaro, D Jeremic, S Djebari, ... IBRO Neuroscience Reports 15, S853, 2023 | | 2023 |
| ALZMETA. APP: ONLINE META-ANALYSIS OF MONOCLONAL ANTIBODIES AGAINST AMYLOID-BETA PEPTIDES IN LARGE PHASE III CLINICAL TRIALS IN ALZHEIMER'S DISEASE D Jeremic, JD Navarro-López, L Jiménez-Díaz IBRO Neuroscience Reports 15, S430, 2023 | | 2023 |
| Systematic characterization of a non-transgenic Amyloid-beta1-42 amyloidosis model: synaptic plasticity and memory deficits in female and male mice R Jimenez-Herrera, A Contreras, D Jeremic, G Iborra-Lazaro, S Djebari, ... | | 2023 |
| Systematic characterization of a non‑transgenic Aβ R Jiménez‑Herrera, A Contreras, S Djebari, J Mulero‑Franco, ... | | 2023 |
